- Recommendation ID
- NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place:
- coordination of eculizumab use through an expert centre
- monitoring systems to record the number of people with a diagnosis of atypical
- haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment
- a national protocol for starting and stopping eculizumab for clinical reasons
- a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.
- Any explanatory notes
- These arrangements include, but are not exclusive to, determining: which patient characteristics allow safe treatment withdrawal after an initial response; whether the patient's disease responds to retreatment with eculizumab if it has relapsed after stopping treatment; and whether the drug dose can be titrated to a marker of response, for example, platelet count, as well as data relating to patient experience of the value offered by eculizumab.
Source guidance details
- Comes from guidance
- Eculizumab for treating atypical haemolytic uraemic syndrome
- Date issued
- January 2015
|Is this a recommendation for the use of a technology only in the context of research?||Yes|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|